Chronic kidney disease progresses through five stages, characterised by declining glomerular filtration rate and progressive loss of kidney function. Early detection and aggressive management of underlying causes and cardiovascular risk factors slow progression. Dialysis and transplantation address end-stage renal disease; stem-cell approaches are being studied to preserve remaining renal function.
Management is stratified by stage and cause. ACE inhibitors and ARBs are first-line for all CKD, providing kidney protection beyond blood-pressure lowering. SGLT2 inhibitors (dapagliflozin, empagliflozin) slow progression by 25–50% regardless of diabetes status and are now standard-of-care. Blood-pressure targets are <120 mmHg systolic (SPRINT criteria). GLP-1 agonists offer kidney and cardiovascular protection. Finerenone, a non-steroidal mineralocorticoid-receptor antagonist, reduces progression and cardiovascular events. Phosphate binders (sevelamer, calcium carbonate) manage hyperphosphataemia in advanced CKD. Erythropoiesis-stimulating agents address anaemia. Stages 4–5 require dialysis—haemodialysis three times weekly or peritoneal dialysis (continuous ambulatory or automated)—and eventual kidney transplantation.
Low-protein diet (0.6–0.8 g/kg/day) may slow glomerular hyperfiltration in early CKD, though benefits are modest. Herbal interventions (astragalus, cordyceps) are used in Traditional Chinese Medicine but lack robust trial evidence. Phosphate restriction through dietary counsel is supportive but must accompany medical therapy.
Stem-cell therapies are being studied for glomerular repair and tubular regeneration, particularly in IgA nephropathy and lupus nephritis. Mesenchymal stem cells may reduce glomerulosclerosis and preserve tubular function. These approaches remain investigational and should be pursued alongside established CKD management. Review candidacy criteria for clinical-trial suitability.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| ACE inhibitor or ARB | Standard | Strong | €100–300/year | Low | None |
| SGLT2 inhibitor (dapagliflozin, empagliflozin) | Standard | Strong | €1,200–1,800/year | Low | None |
| Finerenone (non-steroidal MRA) | Standard | Strong | €1,500–2,000/year | Low | None |
| Low-protein diet + phosphate restriction | Alternative | Moderate | €0 | Low | None |
| Haemodialysis (thrice weekly) | Standard | Strong | €50,000–80,000/year | High | Lifelong (fistula placement 1–2 months) |
| Peritoneal dialysis (continuous ambulatory) | Standard | Strong | €40,000–70,000/year | High | Lifelong (catheter training 2–4 weeks) |
| Glomerular-repair stem-cell therapy | Regenerative | Investigational | €16,000–32,000 (trial-dependent) | Medium | 3–4 weeks |
Not necessarily. Early CKD with optimal management—SGLT2 inhibitors, ACE inhibitors, and tight blood-pressure control—can stabilise or progress very slowly. Only advanced stages (4–5) require dialysis or transplant.
Stem-cell therapy may preserve remaining function and slow progression, particularly in immune-mediated kidney disease, but complete reversal of established scarring is not yet proven.
Haemodialysis is in-centre, thrice weekly, 4 hours per session. Peritoneal dialysis is home-based, daily exchanges. Both have equivalent survival but differ in lifestyle impact and comorbidity effects.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка